Topoisomerase inhibitors as anticancer agents: a patent update

Bibliography

• Schoeffler AJ, Berger JM. DNA topoisomerases: harnessing and constraining energy to govern chromosome topology. Q Rev Biophys 2008;41:41-101
   PubMed Web of Science ®Google Scholar
• Pommier Y, Leo E, Zhang H, Marchand C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol 2010;17:421-33
   PubMed Web of Science ®Google Scholar
• Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 2006;6:789-802
   PubMed Web of Science ®Google Scholar
• Sordet O, Khan QA, Plo I, et al. Apoptotic topoisomerase I-DNA complexes induced by staurosporine-mediated oxygen radicals. J Biol Chem 2004;279:50499-504
   PubMedGoogle Scholar
• Pourquier P, Pilon AA, Kohlhagen G, et al. Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps. Importance of DNA end phosphorylation and camptothecin effects. J Biol Chem 1997;272:26441-7
   PubMed Web of Science ®Google Scholar
• Pourquier P, Ueng LM, Kohlhagen G, et al. Effects of uracil incorporation, DNA mismatches, and abasic sites on cleavage and religation activities of mammalian topoisomerase I. J Biol Chem 1997;272:7792-6
   PubMed Web of Science ®Google Scholar
• Lesher DT, Pommier Y, Stewart L, Redinbo MR. 8-Oxoguanine rearranges the active site of human topoisomerase I. Proc Natl Acad Sci USA 2002;99:12102-7
   PubMedGoogle Scholar
• Chrencik JE, Burgin AB, Pommier Y, et al. Structural impact of the leukemia drug 1-beta-D-arabinofuranosylcytosine (Ara-C) on the covalent human topoisomerase I-DNA complex. J Biol Chem 2003;278:12461-6
   PubMedGoogle Scholar
• Chowdhury AR, Mandal S, Mittra B, et al. Betulinic acid, a potent inhibitor of eukaryotic topoisomerase I: identification of the inhibitory step, the major functional group responsible and development of more potent derivatives. Med Sci Monit 2002;8:BR254-65
   PubMedGoogle Scholar
• Sehested M, Jensen PB. Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle. Biochem Pharmacol 1996;51:879-86
   PubMed Web of Science ®Google Scholar
• Gormley NA, Orphanides G, Meyer A, et al. The interaction of coumarin antibiotics with fragments of DNA gyrase B protein. Biochemistry 1996;35:5083-92
   PubMed Web of Science ®Google Scholar
• Drake FH, Hofmann GA, Mong SM, et al. In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone. Cancer Res 1989;49:2578-83
   PubMed Web of Science ®Google Scholar
• Roca J, Ishida R, Berger JM, et al. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc Natl Acad Sci USA 1994;91:1781-5
   PubMed Web of Science ®Google Scholar
• Giovanella BC, Stehlin JS, Wall ME, et al. DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts. Science 1989;246:1046-8
   PubMed Web of Science ®Google Scholar
• Kohlhagen G, Paull KD, Cushman M, et al. Protein-linked DNA strand breaks induced by NSC 314622, a novel noncamptothecin topoisomerase I poison. Mol Pharmacol 1998;54:50-8
   PubMed Web of Science ®Google Scholar
• Staker BL, Hjerrild K, Feese MD, et al. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc Natl Acad Sci USA 2002;99:15387-92
   PubMed Web of Science ®Google Scholar
• Staker BL, Feese MD, Cushman M, et al. Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. J Med Chem 2005;48:2336-45
   PubMed Web of Science ®Google Scholar
• Ioanoviciu A, Antony S, Pommier Y, et al. Synthesis and mechanism of action studies of a series of norindenoisoquinoline topoisomerase I poisons reveal an inhibitor with a flipped orientation in the ternary DNA-enzyme-inhibitor complex as determined by X-ray crystallographic analysis. J Med Chem 2005;48:4803-14
   PubMedGoogle Scholar
• Song Y, Shao Z, Dexheimer TS, et al. Structure-based design, synthesis, and biological studies of new anticancer norindenoisoquinoline topoisomerase I inhibitors. J Med Chem 2010;53:1979-89
   PubMed Web of Science ®Google Scholar
• Dong G, Sheng C, Wang S, et al. Selection of evodiamine as a novel topoisomerase I inhibitor by structure-based virtual screening and hit optimization of evodiamine derivatives as antitumor agents. J Med Chem 2010;53:7521-31
   PubMed Web of Science ®Google Scholar
• Dong G, Wang S, Miao Z, et al. New tricks for an old natural product: discovery of highly potent evodiamine derivatives as novel antitumor agents by systemic structure-activity relationship analysis and biological evaluations. J Med Chem 2012;55:7593-613
   PubMed Web of Science ®Google Scholar
• Versace RW. The silatecans, a novel class of lipophilic camptothecins. Expert Opin Ther Patent 2003;13:751-60
   Web of Science ®Google Scholar
• Basili S, Moro S. Novel camptothecin derivatives as topoisomerase I inhibitors. Expert Opin Ther Patent 2009;19:555-74
   PubMed Web of Science ®Google Scholar
• Long BH, Balasubramanian BN. Non-camptothecin topoisomerase I active compounds as potential anticancer agents. Expert Opin Ther Patent 2000;10:635-66
   Web of Science ®Google Scholar
• Fox BM, Xiao X, Antony S, et al. Design, synthesis, and biological evaluation of cytotoxic 11-alkenylindenoisoquinoline topoisomerase I inhibitors and indenoisoquinoline-camptothecin hybrids. J Med Chem 2003;46:3275-82
   PubMed Web of Science ®Google Scholar
• Xiao X, Antony S, Pommier Y, Cushman M. Total synthesis and biological evaluation of 22-hydroxyacuminatine. J Med Chem 2006;49:1408-12
   PubMedGoogle Scholar
• Grillet F, Baumlova B, Prevost G, et al. Synthesis and bioevaluation of 22-hydroxyacuminatine analogs. Bioorg Med Chem Lett 2008;18:2143-6
   PubMedGoogle Scholar
• Purdue Research Foundation. Cytotoxic indeno and isoindoloisoquinolones. WO100891; 2004
   Google Scholar
• Cinelli MA, Morrell A, Dexheimer TS, et al. Design, synthesis, and biological evaluation of 14-substituted aromathecins as topoisomerase I inhibitors. J Med Chem 2008;51:4609-19
   PubMed Web of Science ®Google Scholar
• Cinelli MA, Cordero B, Dexheimer TS, et al. Synthesis and biological evaluation of 14-(aminoalkyl-aminomethyl)aromathecins as topoisomerase I inhibitors: investigating the hypothesis of shared structure-activity relationships. Bioorg Med Chem 2009;17:7145-55
   PubMedGoogle Scholar
• Purdue Research Foundation. Oxobenzindolizinoquinolines and uses thereof. WO140467; 2009
   Google Scholar
• Cinelli MA, Morrell AE, Dexheimer TS, et al. The structure-activity relationships of A-ring-substituted aromathecin topoisomerase I inhibitors strongly support a camptothecin-like binding mode. Bioorg Med Chem 2010;18:5535-52
   PubMed Web of Science ®Google Scholar
• Industry foundation of Chonnam National University. Novel isoindolo[2,1-b]isoquinolinone derivatives and anti-cancer agents including them. KR0006033; 2011
   Google Scholar
• Van HT, Cho WJ. Structural modification of 3-arylisoquinolines to isoindolo[2,1-b]isoquinolinones for the development of novel topoisomerase 1 inhibitors with molecular docking study. Bioorg Med Chem Lett 2009;19:2551-4
   PubMed Web of Science ®Google Scholar
• Van HT, Le QM, Lee KY, et al. Convenient synthesis of indeno[1,2-c]isoquinolines as constrained forms of 3-arylisoquinolines and docking study of a topoisomerase I inhibitor into DNA-topoisomerase I complex. Bioorg Med Chem Lett 2007;17:5763-7
   PubMedGoogle Scholar
• Zhang Y, Wu LJ, Tashiro S, et al. Intracellular regulation of evodiamine-induced A375-S2 cell death. Biol Pharm Bull 2003;26:1543-7
   PubMedGoogle Scholar
• Zhang Y, Zhang QH, Wu LJ, et al. Atypical apoptosis in L929 cells induced by evodiamine isolated from Evodia rutaecarpa. J Asian Nat Prod Res 2004;6:19-27
   PubMed Web of Science ®Google Scholar
• Huang DM, Guh JH, Huang YT, et al. Induction of mitotic arrest and apoptosis in human prostate cancer pc-3 cells by evodiamine. J Urol 2005;173:256-61
   PubMed Web of Science ®Google Scholar
• Chan AL, Chang WS, Chen LM, et al. Evodiamine stabilizes topoisomerase I-DNA cleavable complex to inhibit topoisomerase I activity. Molecules 2009;14:1342-52
   PubMedGoogle Scholar
• Taipei Medical University. Pharmaceutical composition for inhibiting topoisomerase I and method for exploiting drug. US0144763; 2010
   Google Scholar
• Pan X, Hartley JM, Hartley JA, et al. Evodiamine, a dual catalytic inhibitor of type I and II topoisomerases, exhibits enhanced inhibition against camptothecin resistant cells. Phytomedicine 2012;19:618-24
   PubMed Web of Science ®Google Scholar
• The Second Military Medical University. Evodiamine compounds, preparation method thereof and application thereof. CN102311434; 2012
   Google Scholar
• Fang SD, Wang LK, Hecht SM. Inhibitors of DNA topoisomerase I isolated from the roots of Zanthoxylum nitidum. J Org Chem 1993;58:5025-7
   Web of Science ®Google Scholar
• Wang LK, Johnson RK, Hecht SM. Inhibition of topoisomerase I function by nitidine and fagaronine. Chem Res Toxicol 1993;6:813-18
   PubMed Web of Science ®Google Scholar
• Janin YL, Croisy A, Riou JF, Bisagni E. Synthesis and evaluation of new 6-amino-substituted benzo[c]phenanthridine derivatives. J Med Chem 1993;36:3686-92
   PubMed Web of Science ®Google Scholar
• Rutgers, The State university of New Jersey. Heterocyclic cytotoxic agents. WO31067; 1999
   Google Scholar
• Makhey D, Li D, Zhao B, et al. Substituted benzo[i]phenanthridines as mammalian topoisomerase-targeting agents. Bioorg Med Chem 2003;11:1809-20
   PubMed Web of Science ®Google Scholar
• Li D, Zhao B, Sim SP, et al. 2,3-Dimethoxybenzo[i]phenanthridines: topoisomerase I-targeting anticancer agents. Bioorg Med Chem 2003;11:521-8
   PubMed Web of Science ®Google Scholar
• Li D, Zhao B, Sim SP, et al. 8,9-methylenedioxybenzo[i]phenanthridines: topoisomerase I-targeting activity and cytotoxicity. Bioorg Med Chem 2003;11:3795-805
   PubMedGoogle Scholar
• Rutgers, The State university of New Jersey. Cytotoxic agents. WO041653; 2003
   Google Scholar
• Rutgers, The State university of New Jersey. Solubilized topoisomerase poisons. WO041660; 2003
   Google Scholar
• Ruchelman AL, Singh SK, Wu X, et al. Diaza- and triazachrysenes: potent topoisomerase-targeting agents with exceptional antitumor activity against the human tumor xenograft, MDA-MB-435. Bioorg Med Chem Lett 2002;12:3333-6
   PubMed Web of Science ®Google Scholar
• Ruchelman AL, Singh SK, Ray A, et al. 5H-Dibenzo[c,h]1,6-naphthyridin-6-ones: novel topoisomerase I-targeting anticancer agents with potent cytotoxic activity. Bioorg Med Chem 2003;11:2061-73
   PubMed Web of Science ®Google Scholar
• Rutgers, The State university of New Jersey. Nitro and amino substituted topoisomerase agents. WO014918; 2004
   Google Scholar
• Singh SK, Ruchelman AL, Li TK, et al. Nitro and amino substitution in the D-ring of 5-(2-dimethylaminoethyl)- 2,3-methylenedioxy-5H-dibenzo[c,h][1,6]naphthyridin-6-ones: effect on topoisomerase-I targeting activity and cytotoxicity. J Med Chem 2003;46:2254-7
   PubMedGoogle Scholar
• Ruchelman AL, Kerrigan JE, Li TK, et al. Nitro and amino substitution within the A-ring of 5H-8,9-dimethoxy-5-(2-N,N-dimethylaminoethyl)dibenzo[c,h][1,6]naphthyridin-6-ones : influence on topoisomerase I-targeting activity and cytotoxicity. Bioorg Med Chem 2004;12:3731-42
   PubMedGoogle Scholar
• Rutgers, The State university of New Jersey. Nitro and amino substituted topoisomerase agents. WO014906; 2004
   Google Scholar
• Ruchelman AL, Zhu S, Zhou N, et al. Dimethoxybenzo[i]phenanthridine-12-carboxylic acid derivatives and 6H-dibenzo[c,h][2,6]naphthyridin-5-ones with potent topoisomerase I-targeting activity and cytotoxicity. Bioorg Med Chem Lett 2004;14:5585-9
   PubMedGoogle Scholar
• Zhu S, Ruchelman AL, Zhou N, et al. 6-Substituted 6H-dibenzo[c,h][2,6]naphthyridin-5-ones: reversed lactam analogues of ARC-111 with potent topoisomerase I-targeting activity and cytotoxicity. Bioorg Med Chem 2006;14:3131-43
   PubMed Web of Science ®Google Scholar
• Rutgers, The State university of New Jersey. Solubilized topoisomerase poison agents. WO051289; 2003
   Google Scholar
• Rutgers, The State university of New Jersey. Topoisomerase poison agents. WO047505; 2003
   Google Scholar
• Purdue Research Foundation. Substituted dibenzonaphthyridines, pharmaceutical uses thereof and processes thereof. WO024437; 2012
   Google Scholar
• Morrell A, Antony S, Kohlhagen G, et al. Synthesis of benz[d]indeno[1,2-b]pyran-5,11-diones: versatile intermediates for the design and synthesis of topoisomerase I inhibitors. Bioorg Med Chem Lett 2006;16:1846-9
   PubMedGoogle Scholar
• Kiselev E, Dexheimer TS, Pommier Y, Cushman M. Design, synthesis, and evaluation of dibenzo[c,h][1,6]naphthyridines as topoisomerase I inhibitors and potential anticancer agents. J Med Chem 2010;53:8716-26
   PubMed Web of Science ®Google Scholar
• Kiselev E, Empey N, Agama K, et al. Dibenzo[c,h][1,5]naphthyridinediones as topoisomerase I inhibitors: design, synthesis, and biological evaluation. J Org Chem 2012;77:5167-72
   PubMed Web of Science ®Google Scholar
• Industry foundation of Chonnam National University. Novel isoquinolinone-based derivatives and anti-cancer agents including them. KR0022951; 2011
   Google Scholar
• Lee SH, Van HT, Yang SH, et al. Molecular design, synthesis and docking study of benz[b]oxepines and 12-oxobenzo[c]phenanthridinones as topoisomerase 1 inhibitors. Bioorg Med Chem Lett 2009;19:2444-7
   PubMedGoogle Scholar
• Rutgers, The State university of New Jersey. Heterocyclic cytotoxic agents. WO32631; 2001
   Google Scholar
• Yu Y, Singh SK, Liu A, et al. Substituted dibenzo[c,h]cinnolines: topoisomerase I-targeting anticancer agents. Bioorg Med Chem 2003;11:1475-91
   PubMedGoogle Scholar
• Ruchelman AL, Singh SK, Ray A, et al. 11H-Isoquino[4,3-c]cinnolin-12-ones; novel anticancer agents with potent topoisomerase I-targeting activity and cytotoxicity. Bioorg Med Chem 2004;12:795-806
   PubMedGoogle Scholar
• Kobayashi Y, Yamashita Y, Fujii N, et al. Inhibitors of DNA topoisomerase I and II isolated from the Coptis rhizomes. Planta Med 1995;61:414-18
   PubMed Web of Science ®Google Scholar
• Zee-Cheng KY, Paull KD, Cheng CC. Experimental antileukemic agents. Coralyne, analogs, and related compounds. J Med Chem 1974;17:347-51
   PubMedGoogle Scholar
• Wang LK, Rogers BD, Hecht SM. Inhibition of topoisomerase I function by coralyne and 5,6-dihydrocoralyne. Chem Res Toxicol 1996;9:75-83
   PubMedGoogle Scholar
• Makhey D, Gatto B, Yu C, et al. Coralyne and related compounds as mammalian topoisomerase I and topoisomerase II poisons. Bioorg Med Chem 1996;4:781-91
   PubMed Web of Science ®Google Scholar
• Rutgers, The State university of New Jersey. Coralyne analogs as topoisomerase inhibitors. WO29106; 1997
   Google Scholar
• Rutgers, The State university of New Jersey. Substituted heterocycles as anti-tumor agents. WO12181; 1998
   Google Scholar
• Makhey D, Yu C, Liu A, et al. Substituted benz[a]acridines and benz[c]acridines as mammalian topoisomerase poisons. Bioorg Med Chem 2000;8:1171-82
   PubMedGoogle Scholar
• Xenova Limited. Benzo[a]phenazin-11-carboxamide derivatives and their use as joint inhibitors of topoisomerase I and II. WO46157; 2001
   Google Scholar
• Vicker N, Burgess L, Chuckowree IS, et al. Novel angular benzophenazines: dual topoisomerase I and topoisomerase II inhibitors as potential anticancer agents. J Med Chem 2002;45:721-39
   PubMed Web of Science ®Google Scholar
• Finlay GJ, Riou JF, Baguley BC. From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives. Eur J Cancer 1996;32A:708-14
   PubMed Web of Science ®Google Scholar
• Purdue Research Foundation. Novel indenoisoquinolines as antineoplastic agents. WO21537; 2000
   Google Scholar
• Strumberg D, Pommier Y, Paull K, et al. Synthesis of cytotoxic indenoisoquinoline topoisomerase I poisons. J Med Chem 1999;42:446-57
   PubMed Web of Science ®Google Scholar
• Jayaraman M, Fox BM, Hollingshead M, et al. Synthesis of new dihydroindeno[1,2-c]isoquinoline and indenoisoquinolinium chloride topoisomerase I inhibitors having high in vivo anticancer activity in the hollow fiber animal model. J Med Chem 2002;45:242-9
   PubMedGoogle Scholar
• Cushman M, Alexandra I, Pommier Y. Synthesis of indenoisoquinoliniums and methods of use. WO089294; 2005
   Google Scholar
• Purdue Research Foundation. The substituted norindenoisoquinolines, synthesis thereof, and methods of use. WO094416; 2011
   Google Scholar
• Purdue Research Foundation. Synthesis of indenoisoquinolines. US0025595; 2006
   Google Scholar
• Morrell A, Antony S, Kohlhagen G, et al. Synthesis of nitrated indenoisoquinolines as topoisomerase I inhibitors. Bioorg Med Chem Lett 2004;14:3659-63
   PubMedGoogle Scholar
• Morrell A, Antony S, Kohlhagen G, et al. A systematic study of nitrated indenoisoquinolines reveals a potent topoisomerase I inhibitor. J Med Chem 2006;49:7740-53
   PubMedGoogle Scholar
• Rutgers, The State university of New Jersey. Nitro and amino substituted heterocycles as topoisomerase I targeting agents. WO014862; 2004
   Google Scholar
• Purdue Research Foundation. Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase I inhibitors. WO162513; 2012
   Google Scholar
• Peterson KE, Cinelli MA, Morrell AE, et al. Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase I inhibitors: investigating the relationships involving stereochemistry, hydrogen bonding, and biological activity. J Med Chem 2011;54:4937-53
   PubMedGoogle Scholar
• Yeungnam University, Industry-academic Cooperation Foundation. Novel 2,4-diphenyl-6-aryl pyridine compound as a potent topoisomerase I and II inhibitor, the preparation method thereof and a composition containing the same. KR0109028; 2011
   Google Scholar
• Zhao LX, Kim TS, Ahn SH, et al. Synthesis, topoisomerase I inhibition and antitumor cytotoxicity of 2,2':6',2"-, 2,2':6',3"- and 2,2':6',4"-terpyridine derivatives. Bioorg Med Chem Lett 2001;11:2659-62
   PubMed Web of Science ®Google Scholar
• Zhao LX, Moon YS, Basnet A, et al. Synthesis, topoisomerase I inhibition and structure-activity relationship study of 2,4,6-trisubstituted pyridine derivatives. Bioorg Med Chem Lett 2004;14:1333-7
   PubMedGoogle Scholar
• Zhao LX, Sherchan J, Park JK, et al. Synthesis, cytotoxicity and structure-activity relationship study of terpyridines. Arch Pharm Res 2006;29:1091-5
   PubMed Web of Science ®Google Scholar
• Basnet A, Thapa P, Karki R, et al. 2,4,6-Trisubstituted pyridines: synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship. Bioorg Med Chem 2007;15:4351-9
   PubMedGoogle Scholar
• Karki R, Thapa P, Kang MJ, et al. Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl pyridines. Bioorg Med Chem 2010;18:3066-77
   PubMed Web of Science ®Google Scholar
• Andersen RJ, Faulkner DJ, Cun-heng H, et al. Metabolites of the marine prosobranch mollusc Lamellaria sp. J Am Chem Soc 1985;107:5492-5
   Web of Science ®Google Scholar
• Quesada AR, Garcia Gravalos MD, Fernandez Puentes JL. Polyaromatic alkaloids from marine invertebrates as cytotoxic compounds and inhibitors of multidrug resistance caused by P-glycoprotein. Br J Cancer 1996;74:677-82
   PubMed Web of Science ®Google Scholar
• Facompre M, Tardy C, Bal-Mahieu C, et al. Lamellarin D: a novel potent inhibitor of topoisomerase I. Cancer Res 2003;63:7392-9
   PubMed Web of Science ®Google Scholar
• Tardy C, Facompre M, Laine W, et al. Topoisomerase I-mediated DNA cleavage as a guide to the development of antitumor agents derived from the marine alkaloid lamellarin D: triester derivatives incorporating amino acid residues. Bioorg Med Chem 2004;12:1697-712
   PubMed Web of Science ®Google Scholar
• PharmaMar, S.A.U. Antitumoral analogs of lamellarins. WO014917; 2004
   Google Scholar
• Bailly C. DNA relaxation and cleavage assays to study topoisomerase I inhibitors. Methods Enzymol 2001;340:610-23
   PubMedGoogle Scholar
• Dexheimer TS, Pommier Y. DNA cleavage assay for the identification of topoisomerase I inhibitors. Nat Protoc 2008;3:1736-50
   PubMed Web of Science ®Google Scholar
• Huang KC, Gao H, Yamasaki EF, et al. Topoisomerase II poisoning by ICRF-193. J Biol Chem 2001;276:44488-94
   PubMed Web of Science ®Google Scholar
• Kerrigan JE, Pilch DS, Ruchelman AL, et al. 5H-8,9-dimethoxy-5-(2-N,N-dimethylaminoethyl)dibenzo[c,h][1,6]naphthyridin-6-ones and related compounds as TOP1-targeting agents: influence of structure on the ternary cleavable complex formation. Bioorg Med Chem Lett 2003;13:3395-9
   PubMedGoogle Scholar
• Wu CC, Li TK, Farh L, et al. Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide. Science 2011;333:459-62
   PubMed Web of Science ®Google Scholar
• Chillemi G, Fiorani P, Benedetti P, Desideri A. Protein concerted motions in the DNA-human topoisomerase I complex. Nucleic Acids Res 2003;31:1525-35
   PubMed Web of Science ®Google Scholar
• Mancini G, D'Annessa I, Coletta A, et al. Structural and dynamical effects induced by the anticancer drug topotecan on the human topoisomerase I - DNA complex. PLoS One 2010;5:e10934
   Google Scholar
• Mancini G, D'Annessa I, Coletta A, et al. Binding of an Indenoisoquinoline to the topoisomerase-DNA complex induces reduction of linker mobility and strengthening of protein-DNA interaction. PLoS One 2012;7:e51354
   Google Scholar
• Seiter K. Toxicity of the topoisomerase II inhibitors. Expert Opin Drug Saf 2005;4:219-34
   PubMedGoogle Scholar
• Pilati P, Nitti D, Mocellin S. Cancer resistance to type II topoisomerase inhibitors. Curr Med Chem 2012;19:3900-6
   PubMedGoogle Scholar
• Nelson EM, Tewey KM, Liu LF. Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4'-(9-acridinylamino)-methanesulfon-m-anisidide. Proc Natl Acad Sci USA 1984;81:1361-5
   PubMed Web of Science ®Google Scholar
• Tewey KM, Chen GL, Nelson EM, Liu LF. Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 1984;259:9182-7
   PubMed Web of Science ®Google Scholar
• Chen GL, Yang L, Rowe TC, et al. Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 1984;259:13560-6
   PubMed Web of Science ®Google Scholar
• Tewey KM, Rowe TC, Yang L, et al. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984;226:466-8
   PubMed Web of Science ®Google Scholar
• Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985;260:14873-8
   PubMed Web of Science ®Google Scholar
• Crespi MD, Ivanier SE, Genovese J, Baldi A. Mitoxantrone affects topoisomerase activities in human breast cancer cells. Biochem Biophys Res Commun 1986;136:521-8
   PubMedGoogle Scholar
• Trask DK, Muller MT. Stabilization of type I topoisomerase-DNA covalent complexes by actinomycin D. Proc Natl Acad Sci USA 1988;85:1417-21
   PubMed Web of Science ®Google Scholar
• Hsiang YH, Jiang JB, Liu LF. Topoisomerase II-mediated DNA cleavage by amonafide and its structural analogs. Mol Pharmacol 1989;36:371-6
   PubMed Web of Science ®Google Scholar
• Yamashita Y, Fujii N, Murakata C, et al. Induction of mammalian DNA topoisomerase I mediated DNA cleavage by antitumor indolocarbazole derivatives. Biochemistry 1992;31:12069-75
   PubMed Web of Science ®Google Scholar
• Chen AY, Yu C, Bodley A, et al. A new mammalian DNA topoisomerase I poison Hoechst 33342: cytotoxicity and drug resistance in human cell cultures. Cancer Res 1993;53:1332-7
   PubMed Web of Science ®Google Scholar